TrakCel Ltd. Adds Cognate BioSevices to Connected Services Program
Connected Services program will link cGMP-manufacturing services with supply chain technology management solution.
TrakCel Ltd., a cell therapy process management and supply chain integration technology, recently introduced Cognate BioServices as the newest member of its Connected Service program, according to a Nov. 10, 2015 press release.
Cognate Bioservices is a fully integrated contract bioservices organization providing development and cGMP-manufacturing services to institutions engaged in the development of cell-based products.
The Connected Services partner ecosystem accelerates cell therapy success by enhancing TrakCel's cell therapy supply chain management platform, according to TrakCel. This improvement to the platform supports therapy success by providing links to participant firms specializing in logistics, cell therapy manufacturing, patient treatment, storage, and compliance.
TrakCel’s technology provides additional transparency into the entire cell therapy process, while providing real-time audit logs and chain-of-custody records of critical components.
Source: TrakCel
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
